Aileron Therapeutics (ALRN)
(Delayed Data from NSDQ)
$3.13 USD
-0.07 (-2.19%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $3.14 +0.01 (0.32%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ALRN 3.13 -0.07(-2.19%)
Will ALRN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ALRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALRN
Are Medical Stocks Lagging Sensus Healthcare (SRTS) This Year?
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
ALRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock
Other News for ALRN
Aileron Therapeutics initiated with bullish view at Brookline
Aileron Therapeutics Announces New Interim CFO Appointment
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024
Aileron Therapeutics GAAP EPS of -$0.86 beats by $0.16